Bicara Therapeutics INC S-1 registration statements

Bicara Therapeutics has filed a registration statement to increase the number of shares available for its public offering by 3,213,236, including an underwriter option.

Bicara Therapeutics is seeking to raise $228.4 million through an IPO to fund the clinical development of its lead drug candidate, ficerafusp alfa, and expand its research into other solid tumors.

Bicara Therapeutics updates its bylaws, detailing stockholder meeting procedures and director responsibilities, as it prepares for its initial public offering.

Bicara Therapeutics advances its IPO plans with an amended S-1 filing, detailing its bifunctional antibody therapy and upcoming clinical trials.

Bicara Therapeutics updates its investor rights agreement, outlining registration rights, information access, and other key provisions for major investors as it prepares for a possible public offering.